FDMT (4D Molecular Therapeutics) Ending Cash Position: $72.49 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $10.99
GF Value $216.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Ending Cash Position?

4D Molecular Therapeutics FDMT +1.38% 55 Ending Cash Position is $72.49 Mil as of Mar. 2026. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $216.99 (Possible Value Trap). The stock has 5 warning signs investors should review.

4D Molecular Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $72.49 Mil.

4D Molecular Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 ($48.56 Mil) to Dec. 2025 ($60.24 Mil) and increased from Dec. 2025 ($60.24 Mil) to Mar. 2026 ($72.49 Mil).

4D Molecular Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($249.11 Mil) to Dec. 2024 ($149.34 Mil) and declined from Dec. 2024 ($149.34 Mil) to Dec. 2025 ($60.24 Mil).

4D Molecular Therapeutics Ending Cash Position Related Terms

4D Molecular Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for 4D Molecular Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4D Molecular Therapeutics Ending Cash Position Chart

4D Molecular Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 153.00 52.35 249.11 149.34 60.24

4D Molecular Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 133.53 77.16 48.56 60.24 72.49
FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4D Molecular Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

4D Molecular Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=149.336+-89.095
=60.24

4D Molecular Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=60.241+12.247
=72.49

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $72.49 Mil mean?
4D Molecular Therapeutics (FDMT) has a Ending Cash Position of $72.49 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on 4D Molecular Therapeutics and its competitors.
Is 4D Molecular Therapeutics' Ending Cash Position too high?
4D Molecular Therapeutics' current Ending Cash Position is $72.49 Mil. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Ending Cash Position compare to TECX and ACHV?
4D Molecular Therapeutics' Ending Cash Position of $72.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on 4D Molecular Therapeutics and its competitors. 4D Molecular Therapeutics's current Ending Cash Position is $72.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $216.99, compared to a current price of $10.99 — trading 94.9% below its estimated fair value. The current Ending Cash Position is $72.49 Mil. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Ending Cash Position is $72.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $10.99 is trading 94.9% below its estimated GF Value™ of $216.99. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Ending Cash Position: $72.49 Mil
  • GF Value™: $216.99 vs. price of $10.99 (94.9% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.99
Price
$216.99
GF Value